Orchard Therapeutics - U.S.

At Orchard Therapeutics, we operate as a leading global biopharmaceutical company dedicated to transforming the lives of patients through the development of innovative hematopoietic stem cell (HSC) gene therapies. Our mission is built on translating pioneering science into curative treatments for severe rare and genetic diseases, addressing profound medical needs where options are historically limited or non-existent.

Who We Are

With our U.S. corporate headquarters anchored in the biotechnology hub of Boston, Massachusetts, and global headquarters in London, United Kingdom, our organisation brings together world-class scientific researchers, clinical development experts, and commercial teams. We partner closely with leading academic institutions, medical centers, and healthcare regulators to pioneer advanced regenerative medicines.

What We Do

We deliver an integrated suite of advanced therapeutic development and commercialisation solutions:

• Ex Vivo Gene Therapy: Utilizing patient-derived hematopoietic stem cells modified outside the body to correct underlying genetic faults before reintroducing them securely to the patient.
• Rare Disease Pipeline Commercialisation: Advancing a comprehensive portfolio of clinical and commercial-stage treatments targeting severe inherited metabolic disorders, primary immune deficiencies, and neurological blood conditions.
• Clinical Research & Global Trials: Collaborating with premier pediatric hospitals and research networks across the U.S. and Europe to conduct rigorous, multi-center clinical trials.
• Regulatory Navigation & Market Access: Engaging proactively with the U.S. Food and Drug Administration (FDA) and international regulatory bodies to secure expedited review pathways, orphan drug designations, and patient access.

Our Approach & Values

• Transformative Potential: Focusing intensely on single-administration, curative therapies designed to address the root genetic cause of a disease rather than just managing chronic symptoms.
• Patient-Centric Urgency: Maintaining an unwavering commitment to children and families affected by severe genetic conditions, ensuring development timelines prioritize urgent medical needs.
• Scientific Rigor & Collaboration: Partnering with world-leading academic and clinical pioneers to translate complex molecular discoveries into safe, scalable commercial realities.

Industry Role

We operate as a Specialised Biopharmaceutical and Gene Therapy Developer. Our role is to act as a pioneer in advanced therapeutic medicinal products (ATMPs), supplying vital genetic treatment frameworks to transform rare disease management across the U.S. and worldwide healthcare landscapes.